Daiichi Sankyo Working with Berkeley Lights' Beacon™ OptoFluidic Platform for Cell Line Development
Program Focuses on Creating Workflow Efficiencies and Accelerating the Drug Development Process
EMERYVILLE, Calif., Oct. 30, 2017 /PRNewswire/ -- Berkeley Lights, Inc. (BLI), a company dedicated to bringing to market transformational platforms for biopharmaceutical processes, announced today a program with global pharmaceutical company Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) focused on using the Beacon platform to accelerate its cell line development workflow. The program includes, screening a pool of recently transfected CHO cells and finding the best clones in 5 days, evaluating and predicting the stability of clones over multiple generations, and establishing monoclonality.
The Beacon platform is capable of screening thousands of clones in less than a week. An initial Daiichi Sankyo study was designed to determine if the Beacon platform can provide a more granular understanding of titer stability by looking at a distribution curve of data points from over a hundred subclones vs the tradition method of looking at only an aggregated value. Several of Daiichi Sankyo's well-characterized clones with different titer stability profiles were subcloned by the BLI system and studied over the course of eight weeks. By looking at a large number of subclones, the Beacon platform provided information about each clonal population, a breadth of information that is not feasible using traditional techniques. Within the first week, the Beacon platform was able to predict the stability of all the well-characterized clones, which aligned with the blinded reference data from Daiichi Sankyo. Understanding stability is a critical part of cell line development. Automating the process on the Beacon platform increases efficiencies and reduces overall costs as well as provides additional insights into the behavior of clonal populations that is not currently available using traditional techniques.
"We are committed to delivering versatile platforms that can transform our customers' workflows – generating time and cost savings," said Keith Breinlinger, PhD, General Manager Life Sciences, SVP Platform Engineering at Berkeley Lights, Inc. "Daiichi Sankyo is a global leader in the creation and production of pharmaceuticals. We look forward to working with Daiichi Sankyo to support their goal of reaching a new level of scalability and precision that is unattainable with manual and semi-automated methods."
To learn more about the Beacon Cell Line Development (CLD) Workflow, visit https://www.berkeleylights.com/beacon-applications/cell-line-development/.
About Berkeley Lights:
Berkeley Lights, Inc. (BLI) develops and commercializes platforms on which many bio-pharmaceutical, genomic, and cellular therapy applications will run. BLI launched its first commercial platform, the Beacon™*, in December 2016. The Beacon platform is ideally suited for cell line development and direct B-cell (plasma and memory cells) antibody discovery workflows. The flexibility of the Beacon platform allows users to automate biological processes and BLI is continuously developing new applications to align with its partners' requirements. BLI's technologies make it possible for customers to accelerate learning and dramatically improve workflows.
* For Research Use Only. Not for use in diagnostic procedures.
For more information, visit http://www.berkeleylights.com/.
SOURCE Berkeley Lights, Inc.
Share this article